Skip to content
DataLookout
Menu

ROAR HMBNCT07589764

Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved 1 year 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Oct 1, 2026 to Dec 1, 2026
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 2 of 5 entries
  2. Notable Primary and study completion dates pushed to Oct 1, 2027
    • Start date: Jul 1, 2026 to Oct 1, 2026
    • Study title shortened, about 4 words
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

ALS Functional Rating Scale, Revised (ALSFRS-R)
Timeframe: Baseline, month 3, month 9
Speech (Listener Effort)
Timeframe: Baseline, month 3, month 9

Secondary (5)

Neurofilament Light Chain levels (blood)
Neurofilament Light Chain levels (Cerebrospinal fluid (CSF))
Insulin-like growth-factor binding protein 7 (IGFBP7) levels (blood)
Insulin-like growth-factor binding protein 7 (IGFBP7) levels (Cerebrospinal fluid (CSF))
Frequency of ALS reversals

Arms and interventions

β-hydroxy-β-methylbutyrate (HMB) administrationExperimental

Drugs: β-hydroxy-β-methylbutyrate (HMB)

Sites

2 sites in 1 country